The Lunenfeld-Tanenbaum Research Institute
Donate Now - Mount Sinai Hospital Foundation of Toronto Lunenfeld QR code
Personal tools
Dr. Rebecca Gladdy
Home Researchers Dr. Rebecca Gladdy

Dr. Rebecca Gladdy

dr. rebecca gladdy

Research Institute
600 University Avenue

Room 1070B
Toronto Ontario M5G 1X5

Tel.: 416-586-4800

► Send Email 


Dr. Rebecca Gladdy


Soft tissue sarcomas (STS) are a diverse group of tumors derived from connective tissue (muscle, fat and bone).

Current treatment of STS is limited primarily to surgical procedures (e.g., removing the sarcoma), with selective use of radiation therapy and the use of conventional chemotherapy in some subtypes of the disease. Unfortunately, these treatment options are limited in their effectiveness and more than 50 per cent of STS patients succumb to this disease.

Researchers have recognized that there is an urgent need to develop subtype-specific molecularly targeted therapeutics that can provide new treatment options unique to each histologic type of sarcoma.

Our program has focused on developing novel therapies for: rhabdomyosarcoma, a tumor mainly found in children and adult sarcomas including leiomyosarcoma and undifferentiated pleomorphic sarcoma.




At a Glance

  • Appointed to the Department of Surgery at Mount Sinai Hospital
  • Surgical oncologist specializing in sarcoma
  • Director of the GI Sarcoma Clinical Research Program
  • Co-Chair of the Toronto International Sarcoma Symposium 


Major Research Activities

The main goals of our Translational Sarcoma Research Program are:

  • to identify targeted agents through the use of high-throughput screens of sarcoma cell lines in the SMART facility at the Lunenfeld-Tanenbaum Research Institute with further validation in the Gladdy lab
  • to develop faithful and genetically flexible mouse models of sarcoma as a tool to functionally validate genomic data and for pre-clinical drug testing
  • to readily translate laboratory findings via clinical trials to sarcoma patients in Ontario.


Selected Publications

  • Hamilton TD, Cannell AJ, Kim M, Catton CN, Blackstein ME, Dickson BC, Gladdy RA, Swallow CJ. Results of Resection for Recurrent or Residual Retroperitoneal Sarcoma After Failed Primary Treatment. Ann Surg Oncol. 2017 Jan 1;24(1):211-218.
  • Gladdy RA, Gupta A, Catton CN. Retroperitoneal Sarcoma: Fact, Opinion, and Controversy. Surg Oncol Clin N Am. 2016 Oct 1;25(4):697-711
  • Burtenshaw SM, Cannell AJ, McAlister ED, Siddique S, Kandel R, Blackstein ME, Swallow CJ, Gladdy RA. Toward Observation as First-line Management in Abdominal Desmoid Tumors. Ann Surg Oncol. 2016 Jul 1;23(7):2212-9. See Comment, Editorial by van Broekhoven DL, Grunhagen DJ, Verhoef C, Ann Surg Oncol.
  • Babichev Y, Kabaroff L, Datti A, Uehling D, Isaac M, Al-Awar R, Prakesch M, Sun RX, Boutros PC, Venier R, Dickson BC, Gladdy RA. PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma. J Transl Med. 2016 Mar 8;14:67.
  • Wong P, Hui A, Su J, Yue S, Haibe-Kains B, Gokgoz N, Xu W, Bruce J, Williams J, Catton C, Wunder JS, Andrulis IL, Gladdy R, Dickson B, O’Sullivan B, Liu FF. Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas. Oncotarget. 2015 Nov 17;6(36):39127-39139.
  • McKinnon T, Venier R, Dickson BC, Kabaroff L, Alkema M, Chen L, Shern JF, Yohe ME, Khan J, Gladdy RA. Kras activation in p53-deficient myoblasts results in high-grade sarcoma formation with impaired myogenic differentiation. Oncotarget. 2015 Jun 10;6(16):14220-14232.
  • Sachdeva M, Mito JK, Lee CL, Zhang M, Li Z, Dodd RD, Cason D, Luo L, Ma Y, Van Mater D, Gladdy R, Lev DC, Cardona DM, Kirsch DG. MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. J Clin Invest. 2014 Oct 1;124(10):4305-19.
  • Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, Le Cesne A, Gladdy RA, Casali PG, Swallow CJ, Gronchi A, Bonvalot S, Raut CP. Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. Ann Surg. 2014 May;259(5):973-8.
  • Kabaroff L, Gupta A, Menezes S, Babichev Y, Kandel RC, Swallow CJ, Dickson BC, Gladdy RA. Development of genetically flexible mouse models of sarcoma using RCAS-TVA mediated gene delivery. PLoS One. 2014 Apr;9(4):e94817.


Recent Publications



Document Actions
Facebook popup Youtube popup Twitter popup RSS popup